Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Passes Fourth COVID-19 Spending Package, Includes $25Bn For Additional Testing, Contact Tracing

Executive Summary

A Paycheck Protection Program and Health Care Enhancement Act bill that would dole out $25bn for additional testing by federal agencies and $75bn to Medicare suppliers providing testing equipment passed the US Senate on 21 April and is headed to the House for a vote.

You may also be interested in...



Latest Coronavirus Bill Passage Adds $100Bn To National Testing Effort

With US House passage of a $484bn coronavirus relief package late on 23 April, Congress has allocated another substantial chunk of funding to support nationwide COVID-19 testing. President Trump signed the bill midday on 24 April.

Feds Would Pick Up Manufacturers’ Costs To Retool Factories To Make COVID-19 Tests, Share IP, In Senate Dems’ Plan

Senate Democrats want the US Congress to pass a bill providing the HHS and FEMA funding and a plan to incentivize manufacturers to retool their facilities to make more coronavirus tests.

Unpacking The $2.2Tn Stimulus Act: Boosts To Medtech And Diagnostics To Fight Coronavirus

A $2.2tn coronavirus stimulus package signed into law by President Trump on 27 March will distribute billions of dollars to federal agencies – including the FDA, the CDC and the FEMA – to hasten approvals of new diagnostics, medical ventilators, respirators and other medtech supplies, conduct more testing of potential COVID-19 patients, and quickly distribute medical supplies where needed most.

Topics

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel